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Immunosuppression enhances atherogenicity of lipid profile Renal transplantation has significantly improved pa-
after transplantation. tient prognosis in chronic renal failure. However, in-
Background. Patients after renal transplantation exhibit high creasing attention is drawn to the high incidence of car-cardiovascular morbidity and mortality because of the accumu-
diovascular morbidity and mortality in renal transplantlation of cardiovascular risk factors such as hypertension or
recipients [1]. The reason for this may be the accumula-dyslipidemia. To elucidate the influence of immunosuppressive
therapy on hyperlipidemia, we studied serum lipids and lipo- tion of risk factors for cardiovascular disease, such as
proteins in renal transplant patients who received prednisone hypertension and dyslipidemia. Besides other contribut-
and either azathioprine or cyclosporine or triple immunosup- ing factors, post-transplant dyslipidemia may be relatedpressive therapy.
to immunosuppressive treatment with corticosteroidsMethods. Serum lipids and lipoprotein levels were measured
[2], cyclosporine [3], azathioprine, or combinations ofin 216 renal transplant patients (81 female and 135 male) with
stable graft function of 4.8 6 2.3 years (range six months to those drugs. Although the impact of dyslipidemia on
eight years) after transplantation. Patients were divided into long-term graft and patient survival in renal transplant
three groups according to one of the following immunosuppres- recipients is generally accepted [4], the influence of im-
sive regimens: (a) prednisone and azathioprine, (b) prednisone
munosuppressive drugs, namely cyclosporine, on dyslipi-and cyclosporine, or (c) prednisone, azathioprine, and cyclospo-
demia is discussed controversially [5], and mechanisms ofrine. Healthy, age- and sex-matched subjects served as controls.
In addition to measurement of total serum lipids, lipoproteins post-transplant dyslipidemia are only poorly understood
were isolated by preparative ultracentrifugation, and lipids [6]. This study was designed to evaluate lipid metabolism
were determined in very low-density lipoprotein (VLDL), low- in well-characterized renal transplant recipients on three
density lipoprotein (LDL), and high-density lipoprotein (HDL) common immunosuppressive regimens in comparisondensity classes.
with matched controls. It therefore quantifies distinctResults. Total serum triglycerides, VLDL, and LDL triglyc-
changes in serum lipids and composition of lipoproteinserides, as well as VLDL cholesterol were elevated in all renal
transplant patients, but elevation was pronounced in female by using preparative ultracentrifugation.
patients. In contrast to total serum cholesterol, which was sig-
nificantly increased in only female patients, elevation of LDL-
triglyceride/apo B ratio was more marked in male patients. METHODS
Patients in group A exhibited only mild hypertriglyceridemia, Overnight fasting blood was drawn from 216 renalwhereas triglyceride enrichment in VLDL and LDL was more
transplant recipients (81 female and 135 male) with func-distinct in group B and was most pronounced in patients of
tioning renal graft 4.8 6 2.3 years after transplantationgroup C. Furthermore, hypertriglyceridemia increased with the
dose of administered prednisone. (range six months to eight years). Lipoproteins were iso-
Conclusions. Immunosuppressive therapy in renal trans- lated by preparative ultracentrifugation [7], and serum
plant patients leads to accumulation of triglyceride-enriched lipids and lipoproteins were determined enzymaticallyVLDL and LDL. Triglyceride enrichment in LDL indicates
(Boehringer Mannheim, Germany). Patients received onethe accumulation of small, dense LDLs, which are known to
of the following immunosuppressive regimens: (a) predni-bear enhanced atherosclerotic risk. This study provides data
that underline the use of individually adjusted immunosuppres- sone and azathioprine (N 5 22), (b) prednisone and cy-
sive therapy and steroid-sparing protocols in renal transplant closporine (N 5 74), or (c) prednisone, azathioprine, and
patients to improve their atherogenic lipoprotein profile. cyclosporine (N 5 120). Three hundred twenty-eight
healthy age- and sex-matched subjects served as controls.
Patients and control subjects on lipid-lowering therapyKey words: cardiovascular risk factors, dyslipidemia, immunosuppres-
sive therapy, renal transplantation. were excluded, and data were analyzed in respect to
concomitant medication. Hypertension was defined as 1999 by the International Society of Nephrology
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Table 1. Lipid levels
NTX Controls
Male Female Total Male Female Total
N 5 135 N 5 81 N 5 216 N 5 201 N 5 127 N 5 328
Serum TG 2.1860.64a 2.3360.52a 2.2460.69a 1.9260.32 1.39 60.31 1.71 60.38
Serum chol 5.8661.36 6.19 61.11a 5.9861.48 5.62 61.01 5.54 61.06 5.59 61.27
VLDL TG 1.4760.82a 1.4960.62a 1.4860.93a 1.3060.28 0.75 60.23 1.08 60.37
VLDL chol 0.8860.22a 0.9660.19a 0.9160.31a 0.6260.14 0.36 60.09 0.52 60.19
LDL TG 0.4760.17a 0.5160.19a 0.4960.22a 0.3660.11 0.38 60.12 0.37 60.15
LDL chol 3.6361.12 3.68 60.93 3.65 61.26 3.76 60.65 3.63 60.67 3.71 60.82
HDL TG 0.2560.09 0.31 60.13 0.27 60.15 0.24 60.07 0.26 60.09 0.25 60.12
HDL chol 1.3360.34 1.53 60.32 1.41 60.37 1.24 60.31 1.58 60.34 1.37 60.44
LDL TG/apoB 0.4560.13a 0.4960.14a 0.4760.18a 0.3360.06 0.37 60.13 0.35 60.16
Data are given in mmol/liter as mean 6 sem. Abbreviations are: Tg, triglycerides; chol, cholesterol; VLDL, very-low density lipoproteins; LDL, low density
lipoproteins; HDL, high density lipoproteins; apoB, apolipoprotein B.
a P , 0.005 vs. controls
whereas VLDL cholesterol was elevated parallel to the
increase in VLDL triglycerides (Table 1), indicating the
predominance of qualitative changes in LDL and quanti-
tative changes in VLDL. Enhancement of triglyceride-
rich VLDL was pronounced in female patients. In addi-
tion, serum cholesterol was found to be increased in both
genders, but elevation was significant in only female sub-
jects. Patients on prednisone and azathioprine exhibited
only minor elevation of triglycerides in VLDL and LDL,
whereas hypertriglyceridemia was more severe in patients
who received prednisone and cyclosporine and was most
pronounced in patients on triple therapy. Triglyceride
enrichment increased with the administered dose of pred-
nisone and was even more distinct in patients with cyclospo-
rine levels higher than 120 ng/ml, independent of steroid
Fig. 1. Low-density lipoprotein (LDL) triglycerides in male (open bar, therapy. Furthermore, subgroup analysis revealed aggra-
N 5 201) and female (hatched bar, N 5 127) control subjects (Co); vation of dyslipidemia in patients on b-blocker therapy.male (open bar, N 5 16) and female (hatched bar, N 5 6) patients on
prednisone and azathioprine (A); male (open bar, N 5 38) and female
(hatched bar, N 5 36) patients on prednisone and cyclosporine (B); and
male (open bar, N 5 81) and female (hatched bar, N 5 39) patients on DISCUSSION
prednisone, azathioprine, and cyclosporine (C). Data are given as mean 6
This study demonstrates distinct changes in serumsem for P , 0.005 (d d) vs. controls, and for P , 0.005 (s) vs. (A).
lipid and lipoprotein concentration and composition re-
lated to immunosuppressive therapy after renal trans-
plantation. Post-transplant dyslipidemia appears to be
documented blood pressure of more than 140/90 mm Hg qualitatively and quantitatively dependent on gender,
on the day of blood drawing. Serum lipid and lipoprotein immunosuppressive drug, and dose. Although some for-
levels are presented as mean 6 sem (Table 1). Differ- mer studies focused mainly on elevation of serum choles-
ences between groups were assessed by Student’s two- terol, our data underline the presence of a remarkable
sided, unpaired t-test for continuous data and by analysis
increase in triglycerides after renal transplantation in
of frequency (chi-squared) for categorical data.
serum, LDL, and VLDL.
Triglyceride-rich LDLs are known to be smaller and
RESULTS exhibit higher density than control LDLs [8]. Because
alteration of size and density contributes to configura-Total serum triglycerides were elevated in all renal
tional changes, small, dense LDL exhibit reduced recep-transplant patients. Lipid analysis of lipoprotein density
tor-specific uptake and therefore bear increased athero-classes revealed an increase in low-density lipoprotein
genicity [9]. This corresponds with the finding that(LDL) (Fig. 1) and very LDL (VLDL) triglycerides as
hypertriglyceridemia is considered to be an independentan underlying mechanism of post-transplant hypertri-
risk factor for cardiovascular disease [10].glyceridemia. In LDL, enrichment of triglycerides oc-
curred without significant changes in LDL cholesterol, Even though other observations are consistent with
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